TWST vs IBRX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
TWST · Twist Bioscience$120.79 ▲ 0.15%
IBRX · ImmunityBio$8.64 ▲ 7.80%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- TWST +290.1%
- IBRX +299.8%
Head to head
| Metric | TWST | IBRX |
|---|---|---|
| Price | $120.79 | $8.64 |
| Change today | ▲ 0.15% | ▲ 7.80% |
| Market cap | $8.01B | $9.15B |
| Return, 3 months | -3.3% | +15.3% |
| Return, year to date | +280.8% | +336.1% |
| Return, 1 year | +299.0% | +305.4% |
| P/E (TTM) | – | – |
| P/B | 18.0 | -8.7 |
| P/E percentile vs own 5y | 8th | 12th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +23.2% | +93.9% |
| Net profit growth (YoY) | -271.9% | -148.9% |
| Gross margin | 52.0% | 99.3% |
| Operating margin | -31.9% | -151.9% |
| Net margin | -31.7% | -598.6% |
| Return on equity | -29.6% | – |
| Analyst target vs. price | +45.8% | +65.0% |
| Analyst buy share | 83% | 100% |
| RSI (14) | 39 | 49 |
| 30-day volatility | 124.5% | 87.7% |
| Max drawdown, 1 year | -41.2% | -42.3% |
| Trend read | Leaning bearish | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- IBRX is the largest of the group by market value.
- IBRX has returned the most over the past year.
- IBRX is growing revenue fastest.
- TWST keeps the most profit per dollar of sales.
- IBRX has been the calmest stock over the last 30 days.